NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement

Cardiol J. 2022;29(2):355-357. doi: 10.5603/CJ.a2021.0158. Epub 2021 Dec 13.

Authors

Marta Piepiorka-Broniecka¹, Tomasz A Michalski², Tomasz Figatowski³, Andrzej Wojtowicz¹, Jaroslaw Jurowiecki¹, Aleksandra Stanska⁴, Jan Rogowski¹, Milosz J Jaguszewski³

Affiliations

¹ Department of Cardiac and Vascular Surgery, Medical University of Gdansk, Poland.
² 1st Department of Cardiology, Medical University of Gdansk, Poland. [email protected].
³ 1st Department of Cardiology, Medical University of Gdansk, Poland.
⁴ Division of Quality of Life Research, Department of Psychology, Medical University of Gdansk, Poland.

No abstract available

MeSH terms

Administration, Oral
Anticoagulants* / therapeutic use
Aortic Valve / surgery
Atrial Fibrillation* / drug therapy
Bioprosthesis
Heart Valve Prosthesis
Humans
Treatment Outcome
Warfarin* / therapeutic use

Substances

Anticoagulants
Warfarin